Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Baricitinib was effective in treating alopecia areata in two major trials.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Gefitinib treatment led to unexpected hair growth in two lung cancer patients.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Nilotinib can cause generalized keratosis pilaris.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Inhibiting ALOX12 can help hair cuticle maturation by increasing S100A3 citrullination.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Ritlecitinib can help about 14,000 people with severe hair loss.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.